| A | B | C | D | E | F | G | H | I | J | K | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | |||||||||||
| 2 | Brand | Indication | MOA | Economics | Approved | IP | Price EUR | 53 | |||
| 3 | Xarelto (rivaroxaban) | VTE | Factor Xa | JNJ | 2025 | Shares | 982.42 | Q123 | |||
| 4 | Eylea (aflibercept) | AMD | VEGF | REGN | expired | MC EUR | 52068.259999999995 | ||||
| 5 | Mirena (intrauterine levonorgestrel) | Birth Control | Hormone | 1 | 12/6/2000 | Cash EUR | 0 | Q123 | |||
| 6 | Kyleena/Jaydess (intrauterine levonorgestrel) | Birth Control | Hormone | 1 | 9/16/2016 | Debt EUR | 36077 | Q123 | |||
| 7 | Adalat (nifedipine) | HTN | CCB | EV EUR | 88145.26 | ||||||
| 8 | Kogenate | ||||||||||
| 9 | Nubeqa (darolutamide)? | ||||||||||
| 10 | Kerendia (finerenone)? | CEO: Werner Baumann | |||||||||
| 11 | Adempas (vericiguat) | ||||||||||
| 12 | Vitrakvi (larotrectinib) | ||||||||||
| 13 | Xofigo | ||||||||||
| 14 | Jivi | ||||||||||
| 15 | Nexavar | ||||||||||
| 16 | Verquvo | ||||||||||
| 17 | Stivarga | ||||||||||
| 18 | Phase | ||||||||||
| 19 | copanlisib | NHL | PI3K | III | |||||||
| 20 | elinzanetant | Vasomotor Symptoms | NK1/3 antagonist | III | |||||||
| 21 | AB-1005 | Parkinson's | AAV2-GDNF | I | |||||||
| 22 | ACTUS-101 | Pompe | I | ||||||||
| 23 | AB-1002 | CHF | I | ||||||||
| 24 | AB-1005 | MSA | AAV2-GDNF | I | |||||||
| 25 | bemdaneprocel | Parkinson's | I | ||||||||
| 26 | BV-101 | Huntington's | gene therapy | I | |||||||
| 27 | LION-101 | LGMD 2I/R9 | gene therapy | I | |||||||
| 28 | adrenomedullin | ARDS | PEG-ADM | I | |||||||
| 29 | asundexian | MACE | FXIa inhibitor | II | |||||||
| 30 | gadoquatrane | MRI | contrast agent | II | |||||||
| 31 | BAY 2395840 | Neuropathic pain | BDKRB1 antagonist | II | |||||||
| 32 | runcaciguat | CKD | sGC activator | II | |||||||
| 33 | zabedosertib | Atopic Dermatitis | IRAK4 | II |